secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2025-05-30T23:59:59+00:00
Accession:  0001213900-25-049451
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharmaceuticals receives Nasdaq delisting notice for equity below $2.5M minimum
--------------------------------------------------------------------------------

- Stockholders' equity of $2,126,662 as of March 31, 2025, below Nasdaq's $2.5M requirement.
- Company has 45 calendar days (until July 7, 2025) to submit a compliance plan to Nasdaq.
- If plan accepted, Nasdaq may grant up to 180 days extension to regain compliance.
- Failure to regain compliance could lead to delisting; company may request a hearing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390025049451/0001213900-25-049451-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390025049451/ea0243908-8k_adial.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-049451

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer